About
Immunity Pharma (IPL) develops therapies for neurodegenerative diseases with an initial focus on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. IPL's drugs are peptides with biologic activity. The peptides stimulate therapeutic cell-signaling processes that are often down-regulated in neurodegenerative diseases. The drugs mitigate disease progression by inducing survival-supporting processes, including reduction of inflammation and reduction of programed cell death (apoptosis). The lead drug, IPL344, is currently entering an open-label, phase-1/2a clinical trial with ALS patients. IPL344 originates from the research laboratory of Professor Irun Cohen at the Weizmann Institute of Science, Israel.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Immunity Pharma's primary focus in drug development?
- Immunity Pharma (IPL) develops therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
- What is the lead drug developed by Immunity Pharma and its current clinical trial stage?
- The lead drug is IPL344, which is currently entering an open-label, phase-1/2a clinical trial with ALS patients.
- Where did the research for IPL344 originate?
- IPL344 originates from the research laboratory of Professor Irun Cohen at the Weizmann Institute of Science, Israel.
- What is the mechanism of action for Immunity Pharma's drugs?
- Immunity Pharma's drugs are peptides that stimulate therapeutic cell-signaling processes, mitigating disease progression by reducing inflammation and programmed cell death (apoptosis).
- When was Immunity Pharma founded and where is it headquartered?
- Immunity Pharma was founded in March 2007 and is headquartered in Jerusalem, Israel.
- What was a significant development for Immunity Pharma in September 2020?
- In September 2020, Immunity Pharma announced promising interim results from its Phase 1/2a study with IPL344 in ALS.
- What is Immunity Pharma's current funding stage?
- According to startupim data, Immunity Pharma is currently in the Pre-Funding stage.
- How many employees does Immunity Pharma currently have?
- Immunity Pharma currently has 6 employees.